期刊论文

Xu, Rui-Hua;Wang, F

英文

Cancer Cell

1535-6108

2022

40

3

277-288.e3

10.1016/j.ccell.2022.02.007

This study is sponsored by Shanghai Junshi Biosciences . The authors thank the patients who participated in this study and their families. This work was supported by the Guangdong Esophageal Cancer Institute Science and Technology Program (grant no. M201905 to F.W.), the National Natural Science Foundation of China (grant nos. 81872011 and 82061160373 to F.W.), the Science and Technology Program of Guangdong (grant no. 2019B020227002 to R.-H.X.), the CAMS Innovation Fund for Medical Sciences (grant no. 2019-I2M-5-036 to R.-H.X.), National Major Science & Technology Major Projects (grant no. 2017ZX09302009 to F.H.), and a Shanghai Science and Technology Committee Technology Grant (grant no. 17431900700 to F.H.).

本校为其他机构

Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial.gov: NCT03829969), 514 patients with treatment-naïve advanced ESCC were randomized (1:1) to receive toripalimab or placebo in combination with paclitaxel plus cisplatin (TP) every 3 weeks for up to 6 cycles, followed by toripalimab or placebo maintenance. At the prespecified final analysis of progression-free survival (PFS), a significant improvement in PFS is observed for the toripalimab...